All T-cell therapy articles
-
NewsNovel CAR T manufacturing process significantly cuts production time
Efficacy findings comparable to those of existing CAR T cell therapies for relapsed/refractory multiple myeloma (r/r MM).
-
ReportPharma Horizons: Cell and Gene Therapy
Cell and gene therapies are transforming modern medicine, offering new hope for patients with complex and previously untreatable diseases. As innovation advances, the industry must overcome challenges in manufacturing, regulation and scalability to unlock the full potential of these groundbreaking therapies.
-
NewsMajor immunotherapy trial sees survival benefit in solid tumours
A key barrier in delivering this type of therapy to patients was overcome in the first-of-a-kind T cell therapy trial, data shows.
-
NewsAstraZeneca to boost cell therapy operations with $300m manufacturing investment
Investment in the US manufacturing facility will accelerate AstraZeneca’s ambition to make next-generation cell therapy a reality, the company asserts.
-
NewsCAR T therapy exhibits encouraging proficiency in R/R LBCL
The first study assessing Yescarta® as second-line therapy for transplant ineligible relapsed/refractory (R/R) large B-cell lymphoma (LBCL) demonstrated durable remission rate in a Phase II trial.
-
NewsUK ATMP clinical trials report 2022 published
T cells were revealed as the most commonly investigated cell type continuing to increase, found CGT Catapult's 2022 UK ATMP clinical trials report.
-
NewsT-cell therapy helps overcome stem cell transplant viral infections
A T-cell therapy that targets six viruses commonly contracted by haematology patients after allogeneic stem cell transplantation, offered 95 percent response in a study.